E. Harris, E. Baguley, R. Asherson, and G. Hughes, Clinical and serological features of the « antiphospholipid syndrome » (APS) (abstract), Bibliographie Br J Rheumatol, vol.26, issue.1, p.19, 1987.

J. L. Beaumont, [Acquired hemorrhagic syndrome caused by a circulating anticoagulant; inhibition of the thromboplastic function of the blood platelets; description of a specific test], Le Sang, vol.25, issue.1, pp.1-15, 1954.

E. J. Bowie, J. H. Thompson, C. A. Pascuzzi, and C. A. Owen, Thrombosis in systemic lupus erythematosus despite circulating anticoagulants, The Journal of Laboratory and Clinical Medicine, vol.62, pp.416-446, 1963.

J. Soulier and M. Boffa, Avortements à répétition, thromboses et anticoagulant circulant antithromboplastine. Trois observations, Nouv Presse Med, vol.9, pp.859-60, 1980.

W. A. Wilson, A. E. Gharavi, T. Koike, M. D. Lockshin, D. W. Branch et al., International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop, Arthritis & Rheumatism, vol.7, issue.7, pp.1309-1320, 1999.
DOI : 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F

S. Miyakis, M. D. Lockshin, T. Atsumi, D. W. Branch, R. L. Brey et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), Journal of Thrombosis and Haemostasis, vol.75, issue.2, pp.295-306, 2006.
DOI : 10.1080/00313020310001643615

M. Galli, P. Comfurius, C. Maassen, H. C. Hemker, M. H. De-baets et al., Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor, The Lancet, vol.335, issue.8705, pp.1544-1591, 1990.
DOI : 10.1016/0140-6736(90)91374-J

H. Matsuura, Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease, The Lancet, vol.336, issue.8708, pp.117-118, 1990.
DOI : 10.1016/0140-6736(90)91697-9

H. Mcneil, Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: ?2-glycoprotein I (apolipoprotein H), 1990.

E. Bevers, Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin, Thromb Haemost, vol.66, pp.629-632, 1991.

E. Previtali, P. Bucciarelli, S. M. Passamonti, and I. Martinelli, Risk Factors for Venous and Arterial Thrombosis, Blood Transfusion = Trasfusione Del Sangue, vol.9, issue.2, pp.120-158, 2011.

H. Bas-de-laat, H. W. Ronald, P. G. Derksen, and . De-groot, ??2-Glycoprotein I, the playmaker of the antiphospholipid syndrome, Clinical Immunology, vol.112, issue.2, pp.161-68, 2004.
DOI : 10.1016/j.clim.2004.02.012

. Giannakopoulos, S. A. Bill, and . Krilis, The Pathogenesis of the Antiphospholipid Syndrome, New England Journal of Medicine, vol.368, issue.11, pp.1033-1077, 2013.
DOI : 10.1056/NEJMra1112830

P. G. Laat and . De-groot, Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I, Current Rheumatology Reports, vol.46, issue.1, pp.70-76, 2011.
DOI : 10.1007/s11926-010-0144-8

G. M. Iverson, E. J. Victoria, and D. M. Marquis, Anti-??2 glycoprotein I (??2GPI) autoantibodies recognize an epitope on the first domain of ??2GPI, Proceedings of the National Academy of Sciences, vol.70, issue.1, pp.15542-15588, 1998.
DOI : 10.1016/0076-6879(87)54085-X

J. Nimpf, H. Wurm, and G. M. Kostner, ??2-glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation, Atherosclerosis, vol.63, issue.2-3, pp.109-123, 1987.
DOI : 10.1016/0021-9150(87)90110-9

I. Schousboe, Beta 2-Glycoprotein I: A Plasma Inhibitor of the Contact Activation of the Intrinsic Blood Coagulation Pathway, Blood, vol.66, issue.17 5, pp.1086-91, 1985.

I. Schousboe and M. S. Rasmussen, Synchronized Inhibition of the Phospholipid Mediated Autoactivation of Factor XII in Plasma by Beta 2-Glycoprotein I and Anti-Beta 2-Glycoprotein I, Thrombosis and Haemostasis, vol.73, issue.5, pp.798-804, 1995.

J. Nimpf, E. M. Bevers, P. H. Bomans, U. Till, H. Wurm et al., Prothrombinase activity of human platelets is inhibited by ??2-glycoprotein-I, Biochimica et Biophysica Acta (BBA) - General Subjects, vol.884, issue.1, pp.142-191, 1986.
DOI : 10.1016/0304-4165(86)90237-0

W. Shi, B. H. Chong, P. J. Hogg, and C. N. Chesterman, Anticardiolipin Antibodies Block the Inhibition by Beta 2-Glycoprotein I of the Factor Xa Generating Activity of Platelets, Thrombosis and Haemostasis, vol.70, issue.2, pp.342-387, 1993.

D. M. Keeling, A. J. Wilson, I. J. Mackie, D. A. Isenberg, and S. J. Machin, Role of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro., Journal of Clinical Pathology, vol.46, issue.10, pp.908-919, 1993.
DOI : 10.1136/jcp.46.10.908

P. Meroni, M. O. Luigi, E. Borghi, F. Raschi, and . Tedesco, Pathogenesis of antiphospholipid syndrome: understanding the antibodies, Nature Reviews Rheumatology, vol.39, issue.6, pp.330-369, 2011.
DOI : 10.1038/nrrheum.2011.52

R. T. Urbanus, H. M. Ronald, P. G. Derksen, and . De-groot, Current insight into diagnostics and pathophysiology of the antiphospolipid syndrome, Blood Reviews, vol.22, issue.2, pp.93-105, 2008.
DOI : 10.1016/j.blre.2007.09.001

G. Espinosa, R. Cervera, J. Font, and Y. Shoenfeld, Antiphospholipid syndrome: pathogenic mechanisms, Autoimmunity Reviews, vol.2, issue.2, pp.86-93, 2003.
DOI : 10.1016/S1568-9972(02)00144-1

S. Yasuda, M. Bohgaki, T. Atsumi, and T. Koike, Pathogenesis of antiphospholipid antibodies: impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway, Immunobiology, vol.210, issue.10, pp.775-80, 2005.
DOI : 10.1016/j.imbio.2005.10.009

. Ruiz-irastorza, M. Guillermo, W. Crowther, M. A. Branch, and . Khamashta, Antiphospholipid syndrome, The Lancet, vol.376, issue.9751, pp.1498-1509, 2010.
DOI : 10.1016/S0140-6736(10)60709-X

P. G. Groot, B. De, R. H. Lutters, T. Derksen, J. C. Lisman et al., Lupus anticoagulants and the risk of a first episode of deep venous thrombosis, Journal of Thrombosis and Haemostasis, vol.97, issue.9, pp.1993-97, 2005.
DOI : 10.1111/j.1538-7836.2005.01485.x

R. T. Urbanus, B. Siegerink, M. Roest, F. R. Rosendaal, P. G. De-groot et al., Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study, The Lancet Neurology, vol.8, issue.11, pp.998-1005, 2009.
DOI : 10.1016/S1474-4422(09)70239-X

R. A. Asherson, The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment, Lupus, vol.5, issue.2_suppl, pp.55-62, 1998.
DOI : 10.1177/096120339800700214

M. Galli, D. Luciani, G. Bertolini, and T. Barbui, Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature, Blood, vol.101, issue.5, pp.1827-1859, 2003.
DOI : 10.1182/blood-2002-02-0441

K. De-laat, P. G. Mertens, and . De-groot, Mechanisms of Disease: antiphospholipid antibodies???from clinical association to pathologic mechanism, Nature Clinical Practice Rheumatology, vol.1, issue.4, pp.192-99, 2008.
DOI : 10.1038/ncprheum0740

M. J. Simmelink, R. H. Derksen, J. Arnout, and P. G. De-groot, A simple method to discriminate between beta2-glycoprotein I- and prothrombin-dependent lupus anticoagulants, Journal of Thrombosis and Haemostasis, vol.116, issue.4, pp.740-787, 2003.
DOI : 10.1016/S0049-3848(98)00144-3

R. H. De-laat, R. T. Derksen, M. Urbanus, P. G. Roest, and . De-groot, ??2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome, Blood, vol.104, issue.12, pp.3598-3602, 2004.
DOI : 10.1182/blood-2004-03-1107

J. P. Viard, Z. Amoura, and J. F. Bach, Anti-??2-Glycoprotein I antibodies and thrombosis, Clinical Reviews in Allergy & Immunology, vol.93, issue.4, Suppl., pp.67-72, 1995.
DOI : 10.1007/BF02772250

R. H. De-laat, R. T. Derksen, P. G. Urbanus, and . De-groot, IgG antibodies that recognize epitope Gly40-Arg43 in domain I of ??2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis, Blood, vol.105, issue.4, pp.1540-1585, 2005.
DOI : 10.1182/blood-2004-09-3387

. Giannakopoulos, F. Bill, Y. Passam, S. A. Ioannou, and . Krilis, How we diagnose the antiphospholipid syndrome, Blood, vol.113, issue.5, pp.985-94, 2009.
DOI : 10.1182/blood-2007-12-129627

M. Galli, D. Luciani, G. Bertolini, and T. Barbui, Anti-??2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome, Blood, vol.102, issue.8, pp.2717-2740, 2003.
DOI : 10.1182/blood-2002-11-3334

G. Iverson, S. Michael, E. J. Reddel, K. A. Victoria, Y. Cockerill et al., Use of Single Point Mutations in Domain I of ??2-Glycoprotein I to Determine Fine Antigenic Specificity of Antiphospholipid Autoantibodies, The Journal of Immunology, vol.169, issue.12, pp.7097-7103, 1950.
DOI : 10.4049/jimmunol.169.12.7097

Y. Ioannou, C. Pericleous, I. Giles, D. S. Latchman, D. A. Isenberg et al., Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human ??2-glycoprotein I: Mutation studies including residues R39 to R43, Arthritis & Rheumatism, vol.52, issue.1, pp.280-90, 2007.
DOI : 10.1002/art.22306

M. Galli, G. Borrelli, E. M. Jacobsen, R. M. Marfisi, G. Finazzi et al., Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study, Blood, vol.110, issue.4, pp.1178-83, 2007.
DOI : 10.1182/blood-2007-01-066043

E. N. Harris, S. S. Pierangeli, and A. E. Gharavi, Diagnosis of the antiphospholipid syndrome: A proposal for use of laboratory tests, Lupus, vol.96, issue.12, pp.144-148, 1998.
DOI : 10.1177/096120339800700232

M. Sanmarco, S. Gayet, M. Alessi, M. Audrain, E. De-maistre et al., Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies, Thrombosis and Haemostasis, vol.97, issue.6, pp.949-54, 2007.
DOI : 10.1160/TH06-10-0604

T. Sugi, H. Matsubayashi, A. Inomo, L. Dan, and T. Makino, Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss*, Journal of Obstetrics and Gynaecology Research, vol.267, issue.2, pp.326-358, 2004.
DOI : 10.1046/j.1538-7836.2003.00022.x

D. Erkan, C. L. Aguiar, D. Andrade, H. Cohen, M. J. Cuadrado et al., 14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends, 14th International Congress on Antiphospholipid Antibodies: Task Force Report on Antiphospholipid Syndrome Treatment Trends, pp.685-96, 2014.
DOI : 10.1016/j.autrev.2014.01.053

H. Cohen, B. J. Hunt, M. Efthymiou, R. J. Deepa, I. J. Arachchillage et al., Rivaroxaban versus Warfarin to Treat Patients with Thrombotic Antiphospholipid Syndrome, with or without Systemic Lupus Erythematosus (RAPS): A Randomised, Controlled, Open-Label The Lancet, pp.426-436, 2016.

D. J. Wallace, Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?, Arthritis & Rheumatism, vol.8, issue.12, pp.1435-1471, 1987.
DOI : 10.1002/art.1780301219

H. Jung, R. Bobba, J. Su, Z. Shariati-sarabi, D. D. Gladman et al., The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus, Arthritis & Rheumatism, vol.44, issue.3, pp.863-68, 2010.
DOI : 10.1002/art.27289

R. Kaiser, C. M. Cleveland, and L. A. Criswell, Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort, Annals of the Rheumatic Diseases, vol.68, issue.2, pp.238-279, 2009.
DOI : 10.1136/ard.2008.093013

M. Petri, G. Law, H. Fang, and L. Magder, Hydroxychloroquine reduces thrombosis (both arterial and venous) in systemic lupus erythematosus, but only in antiphospholipid positive patients

M. G. Tektonidou, K. Laskari, D. B. Panagiotakos, and H. M. Moutsopoulos, Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies, Arthritis Care & Research, vol.52, issue.Suppl, pp.29-36, 2009.
DOI : 10.1002/art.24232

A. Schmidt-tanguy, J. Voswinkel, D. Henrion, J. F. Subra, L. Loufrani et al., Antithrombotic Effects of Hydroxychloroquine in Primary Antiphospholipid Syndrome Patients, Journal of Thrombosis and Haemostasis: JTH, vol.52, issue.11 10, pp.1927-1956, 2013.

V. Pengo, A. Banzato, E. Bison, G. Zoppellaro, S. Jose et al., Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial, Lupus, vol.11, issue.3, pp.301-307, 2016.
DOI : 10.1001/jama.291.5.576

D. Erkan, J. Vega, G. Ramón, E. Kozora, and M. D. Lockshin, A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome, Arthritis & Rheumatism, vol.12, issue.2, pp.464-71, 2013.
DOI : 10.1002/art.37759

R. Furie, M. Petri, O. Zamani, R. Cervera, D. J. Wallace et al., A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, Arthritis & Rheumatism, vol.62, issue.Suppl, pp.3918-3948, 2011.
DOI : 10.1002/art.30613

S. V. Navarra, R. M. Guzmán, A. E. Gallacher, S. Hall, R. A. Levy et al., Efficacy and Safety of Belimumab in Patients with Active Systemic Lupus Erythematosus: A Randomised

W. Stohl, F. Hiepe, K. M. Latinis, M. Thomas, M. A. Scheinberg et al., Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus, Arthritis & Rheumatism, vol.111, issue.7, pp.2328-2365, 2012.
DOI : 10.1002/art.34400

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3350827

B. E. Lonze, L. Andrew, R. A. Singer, and . Montgomery, Eculizumab and Renal Transplantation in a Patient with CAPS, New England Journal of Medicine, vol.362, issue.18, pp.1744-1789, 2010.
DOI : 10.1056/NEJMc0910965

I. Shapira, D. Andrade, S. L. Allen, and J. E. Salmon, Brief Report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab, Arthritis & Rheumatism, vol.362, issue.8, pp.2719-2742, 2012.
DOI : 10.1002/art.34440

B. E. Lonze, A. A. Zachary, C. M. Magro, N. M. Desai, B. J. Orandi et al., Eculizumab Prevents Recurrent Antiphospholipid Antibody Syndrome and Enables Successful Renal Transplantation, American Journal of Transplantation, vol.64, issue.2, pp.459-65, 2014.
DOI : 10.1111/ajt.12540

V. Pengo, A. Ruffatti, C. Legnani, P. Gresele, D. Barcellona et al., Clinical course of high-risk patients diagnosed with antiphospholipid syndrome, Journal of Thrombosis and Haemostasis, vol.106, issue.2, pp.237-279, 2010.
DOI : 10.1111/j.1538-7836.2009.03674.x

D. Saadoun, J. Piette, D. Wahl, and N. Costedoat-chalumeau, Traitement du syndrome des anticorps antiphospholipides, La Revue de M??decine Interne, vol.33, issue.4, pp.217-239, 2012.
DOI : 10.1016/j.revmed.2012.01.007

T. Tarr, G. L. , Y. Shoenfeld, G. Szegedi, and E. Kiss, Clinical Thrombotic Manifestations in SLE Patients With and Without Antiphospholipid Antibodies: A 5-year Follow-up, Clinical Reviews in Allergy & Immunology, vol.2, issue.1, pp.131-168, 2007.
DOI : 10.1007/s12016-007-0009-8

. Pengo, A. Vittorio, C. Biasiolo, U. Pegoraro, F. Cucchini et al., Antibody profiles for the diagnosis of antiphospholipid syndrome, Thrombosis and Haemostasis, vol.93, issue.6, pp.1147-52, 2005.
DOI : 10.1160/TH04-12-0839

V. Pengo, A. Ruffatti, T. Del-ross, M. Tonello, S. Cuffaro et al., Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile, Journal of Thrombosis and Haemostasis, vol.38, issue.8, pp.1527-1558, 2013.
DOI : 10.1111/jth.12264

. Pengo, A. Vittorio, C. Ruffatti, S. Legnani, T. Testa et al., Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study, Blood, vol.118, issue.17, pp.4714-4732, 2011.
DOI : 10.1182/blood-2011-03-340232

C. V. Pollack, A. Paul, J. Reilly, S. Eikelboom, P. Glund et al., Idarucizumab for Dabigatran Reversal, New England Journal of Medicine, vol.373, issue.6, pp.511-531, 2015.
DOI : 10.1056/NEJMoa1502000

. Sciascia, M. J. Savino, M. Cuadrado, and . Karim, Management of Infection in Systemic Lupus Erythematosus Best Practice & Research, Clinical Rheumatology, vol.27, issue.3, pp.377-89, 2013.

K. Otomo, T. Atsumi, O. Amengual, Y. Fujieda, M. Kato et al., Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events, Arthritis & Rheumatism, vol.34, issue.2, pp.504-516, 2012.
DOI : 10.1002/art.33340

. Sciascia, G. Savino, V. Sanna, D. Murru, M. A. Roccatello et al., GAPSS: the Global Anti-Phospholipid Syndrome Score, Rheumatology, vol.52, issue.8, pp.1397-1403, 2013.
DOI : 10.1093/rheumatology/kes388

URL : http://hdl.handle.net/2318/142476

. Sciascia, G. Savino, V. Sanna, D. Murru, M. A. Roccatello et al., The global anti-phospholipid syndrome score in primary APS, Rheumatology, vol.54, issue.1, pp.134-172, 2015.
DOI : 10.1093/rheumatology/keu307

G. R. Hughes and M. A. Khamashta, Seronegative antiphospholipid syndrome, Annals of the Rheumatic Diseases, vol.62, issue.12, p.1127, 2003.
DOI : 10.1136/ard.2003.006163

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1754381

P. Meroni, C. B. Luigi, F. Chighizola, M. Rovelli, and . Gerosa, Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers, Arthritis Research & Therapy, vol.16, issue.2, p.209, 2014.
DOI : 10.1182/blood-2011-01-333617

J. A. Gómez-puerta and R. Cervera, Diagnosis and classification of the antiphospholipid syndrome, Journal of Autoimmunity, vol.48, issue.49, pp.48-49, 2014.
DOI : 10.1016/j.jaut.2014.01.006

O. Wu, N. Bayoumi, M. Vickers, and P. Clark, ABO(H) blood groups and vascular disease: a systematic review and meta-analysis, Journal of Thrombosis and Haemostasis, vol.359, issue.Suppl. 2, pp.62-71, 2007.
DOI : 10.1111/j.1538-7836.2007.02818.x

D. Villalta, M. G. Alessio, M. Tampoia, A. Da-re, S. Stella et al., Accuracy of the First Fully Automated Method for Anti-cardiolipin and Anti-??2 Glycoprotein I Antibody Detection for the Diagnosis of Antiphospholipid Syndrome, Annals of the New York Academy of Sciences, vol.34, issue.1, pp.21-27, 2009.
DOI : 10.1111/j.1749-6632.2009.04659.x

L. Despierres, A. Beziane, G. Kaplanski, B. Granel, J. Serratrice et al., Contribution of anti-??2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and non-thrombotic patients, Rheumatology, vol.53, issue.7, pp.1215-1233, 2014.
DOI : 10.1093/rheumatology/keu003

H. Kelchtermans, L. Pelkmans, B. De-laat, and K. M. Devreese, IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis, Journal of Thrombosis and Haemostasis, vol.9, issue.Suppl. 1, pp.1530-1578, 2016.
DOI : 10.1007/s11926-007-0034-x

M. Be?arevi?, D. Mirkovi?, and S. Ignjatovi?, Double positivity of the IgG isotype of both anticardiolipin and anti-??2gpI antibodies is associated with the highest number of vascular impairment parameters in patients with primary antiphospholipid syndrome: preliminary data, Clinical Rheumatology, vol.12, issue.1, pp.2947-54, 2016.
DOI : 10.1016/j.humimm.2015.10.008

A. Ruffatti, T. D. Ross, M. Ciprian, M. T. Bertero, S. Sciascia et al., Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study, Annals of the Rheumatic Diseases, vol.70, issue.6, pp.1083-86, 2011.
DOI : 10.1136/ard.2010.142042

D. Erkan, Y. Yazici, M. G. Peterson, L. Sammaritano, and M. D. Lockshin, A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome, Rheumatology, vol.41, issue.8, pp.924-953, 2002.
DOI : 10.1093/rheumatology/41.8.924

. Girón-gonzález, A. José, E. García-del-río, C. Rodríguez, J. Rodríguez-martorell et al., Antiphospholipid Syndrome and Asymptomatic Carriers of Antiphospholipid Antibody: Prospective Analysis of 404 Individuals, The Journal of Rheumatology, vol.83, issue.31 8, pp.1560-67, 2004.

V. Pengo, A. Tripodi, G. Reber, J. H. Rand, T. L. Ortel et al., Update of the guidelines for lupus anticoagulant detection, Update of the Guidelines for Lupus Anticoagulant Detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis, pp.1737-1777, 2009.
DOI : 10.1111/j.1538-7836.2009.03555.x

J. O. Latino, S. Udry, F. M. Aranda, S. D. Perés-wingeyer, D. S. Romero et al., Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile, Lupus, vol.47, issue.3, 2017.
DOI : 10.1016/j.thromres.2015.04.031

J. L. Zhao, Y. D. Sun, Y. Zhang, D. Xu, Q. Wang et al., [The clinical manifestations and thrombotic risk factors in primary antiphospholipid syndrome], Zhonghua Nei Ke Za Zhi, vol.55, issue.86 5, pp.386-91, 2016.

A. Ruffatti, T. Del-ross, M. Ciprian, M. Nuzzo, M. Rampudda et al., Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study, Annals of the Rheumatic Diseases, vol.68, issue.3, pp.397-99, 2009.
DOI : 10.1136/ard.2008.096669

G. Finazzi, V. Brancaccio, M. Moia, N. Ciaverella, M. G. Mazzucconi et al., Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the italian registry, The American Journal of Medicine, vol.100, issue.5, pp.530-566, 1996.
DOI : 10.1016/S0002-9343(96)00060-5